CORT
HEALTHCARECorcept Therapeutics Inc
$52.15+0.82 (+1.60%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CORT Today?
No stock-specific AI insight has been generated for CORT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$28.66$91.00
$52.15
Fundamentals
Market Cap$5.6B
P/E Ratio149.0
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding107.4M
CORT News
52 articles- Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS Data - Has The Bull Case Changed?Yahoo Finance·May 7, 2026
- CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin PressuresYahoo Finance·May 5, 2026
- Corcept (CORT) Q1 2026 Earnings TranscriptMotley Fool·May 4, 2026
- Corcept (CORT) Q4 2025 Earnings TranscriptMotley Fool·May 4, 2026
- Corcept (CORT) Q1 2025 Earnings TranscriptMotley Fool·May 4, 2026
- Corcept (CORT) Upgraded After Key Regulatory Approval for LifyorliYahoo Finance·May 2, 2026
- CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook RaisedYahoo Finance·May 1, 2026
- Corcept Therapeutics Incorporated Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...Yahoo Finance·May 1, 2026
- Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 1, 2026
- Corcept Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue EstimatesYahoo Finance·Apr 30, 2026
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateYahoo Finance·Apr 30, 2026
- Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral SclerosisYahoo Finance·Apr 30, 2026
- Corcept Earnings: What To Look For From CORTYahoo Finance·Apr 29, 2026
- Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival DataYahoo Finance·Apr 29, 2026
- A Look At Corcept Therapeutics (CORT) Valuation After FDA Approval Of Lifyorli And Positive ROSELLA Trial ResultsYahoo Finance·Apr 24, 2026
- April 2026's High Insider Ownership Growth LeadersYahoo Finance·Apr 24, 2026
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallYahoo Finance·Apr 23, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTGlobeNewswire Inc.·Apr 21, 2026
- 1 Cash-Producing Stock for Long-Term Investors and 2 We IgnoreYahoo Finance·Apr 21, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 21, 2026
- CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21stGlobeNewswire Inc.·Apr 20, 2026
- CORT 3-DAY DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant FailureGlobeNewswire Inc.·Apr 19, 2026
- CORT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORTGlobeNewswire Inc.·Apr 18, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 17, 2026
- CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit — The Gross Law FirmGlobeNewswire Inc.·Apr 17, 2026
- CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant FailureGlobeNewswire Inc.·Apr 14, 2026
- Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the FirmGlobeNewswire Inc.·Apr 13, 2026
- Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORTGlobeNewswire Inc.·Apr 13, 2026
- INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 10, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 10, 2026
- Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Corcept Therapeutics Incorporated (CORT), Lakeland Industries, Inc. (LAKE), and Navan, Inc. (NAVN) Announced by Holzer & Holzer, LLCGlobeNewswire Inc.·Apr 9, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 7, 2026
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORTGlobeNewswire Inc.·Apr 6, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 3, 2026
- CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 3, 2026
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORTGlobeNewswire Inc.·Apr 2, 2026
- Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 1, 2026
- CORT INVESTOR UPDATE: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent LossGlobeNewswire Inc.·Mar 31, 2026
Price Data
Open$51.69
Previous Close$51.33
Day High$52.98
Day Low$51.00
52 Week High$91.00
52 Week Low$28.66
52-Week Range
$28.66$91.00
$52.15
Fundamentals
Market Cap$5.6B
P/E Ratio149.0
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding107.4M
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—